Cordish Dixon Private Equity Fund III (ASX:CD3) Research & Development: A$0.00 Mil (TTM As of Mar. 2026)


ASX:CD3 Cordish Dixon Private Equity Fund III ASX:CD3
33 GF Score
Price A$0.88
View Full Analysis

What is Cordish Dixon Private Equity Fund III Research & Development?

Cordish Dixon Private Equity Fund III ASX:CD3 33 Research & Development is A$0.00 Mil as of Mar. 2026. GuruFocus rates ASX:CD3 with a GF Score™ of 33/100.

Research & Development is the aggregate amount of research and development expenses during the year. Cordish Dixon Private Equity Fund III's Research & Development for the six months ended in Mar. 2026 was A$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.00 Mil.

Cordish Dixon Private Equity Fund III  (ASX:CD3) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cordish Dixon Private Equity Fund III Research & Development Related Terms

Cordish Dixon Private Equity Fund III Research & Development Historical Data

* Premium members only.

The historical data trend for Cordish Dixon Private Equity Fund III's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cordish Dixon Private Equity Fund III Research & Development Chart

Cordish Dixon Private Equity Fund III Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cordish Dixon Private Equity Fund III Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:CD3
33GF Score
Cordish Dixon Private Equity Fund III ASX:CD3
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cordish Dixon Private Equity Fund III Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.00 Mil mean?
Cordish Dixon Private Equity Fund III (ASX:CD3) has a Research & Development of A$0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Cordish Dixon Private Equity Fund III and its competitors.
Is Cordish Dixon Private Equity Fund III's Research & Development too high?
Cordish Dixon Private Equity Fund III's current Research & Development is A$0.00 Mil. Overall, Cordish Dixon Private Equity Fund III has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Cordish Dixon Private Equity Fund III's Research & Development compare to BLK and BX?
Cordish Dixon Private Equity Fund III's Research & Development of A$0.00 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Asset Management company?
A good Research & Development depends on the Asset Management industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cordish Dixon Private Equity Fund III and its competitors. Cordish Dixon Private Equity Fund III's current Research & Development is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordish Dixon Private Equity Fund III stock overvalued right now?
Cordish Dixon Private Equity Fund III (ASX:CD3) has a current Research & Development of A$0.00 Mil. The current Research & Development is A$0.00 Mil. Cordish Dixon Private Equity Fund III's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cordish Dixon Private Equity Fund III (ASX:CD3), the current Research & Development is A$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cordish Dixon Private Equity Fund III Business Description

Address Level 44, 101 Collins Street, Melbourne, VIC, AUS, 3000
Cordish Dixon Private Equity Fund III invests in small-to-mid-market private investment funds and privately held companies with a predominant focus in the United States. The objective of the Fund is to achieve capital growth over a medium- to long-term investment time horizon through exposure to a portfolio of investments in small and mid-market private investment funds and privately held companies. Its private investment funds focus on a range of industries, including health care, business services, software businesses, and food and consumer products.
33GF Score

Get the complete analysis for ASX:CD3

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.88
Price